

SUPPLEMENTARY ADMISSION DOCUMENT

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt about the contents of this Document or as to what action you should take, you should consult an independent professional adviser authorised under the Financial Services and Markets Act 2000 ("FSMA") if you are in the UK or, if not resident in the UK, another appropriately authorised independent financial adviser who specialises in advising on the acquisition of shares and other securities. If you have sold or transferred all your Ordinary Shares you should send this document together with the accompanying Form of Proxy as soon as possible to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for onward transmission to the purchaser or transferee. If you have sold or transferred only part of your holding of Ordinary Shares in the Company, you should retain these documents, and consult the person through whom the sale or transfer was effected.

This document is supplemental to the Admission Document dated 17 March 2021 ("Admission Document") and should be read in conjunction with such document drawn up in compliance with the requirements of the AQSE Growth Market Rules and is being issued in connection with the proposed re-admission of AfriAg Global plc to the AQSE Growth Market. This Document does not constitute and the Company is not making an offer to the public within the meaning of sections 85 and 102B of FSMA. Therefore, this Document is not an approved prospectus for the purposes of and as defined in section 85 of FSMA, has not been prepared in accordance with the Prospectus Rules and its contents have not been approved by the Financial Conduct Authority or any other authority which could be a competent authority for the purposes of the Prospectus Directive. Further, the contents of this Document have not been approved by an authorised person for the purposes of section 21 of FSMA. This Document will not be filed with, or approved by, the Financial Conduct Authority or any other government or regulatory authority in the UK or elsewhere.

The Existing Directors and the Proposed Directors, whose names are set out on page 4 of this Document, accept full responsibility, collectively and individually (including any expressions of opinion), for the information contained in this Document. To the best of the knowledge and belief of the Existing Directors and the Proposed Directors (who have taken all reasonable care to ensure that such is the case), the information contained in this Document is in accordance with the facts and there is no other material information the omission of which is likely to affect the import of such information.

AFRIAG GLOBAL PLC

(a company incorporated and registered in the Isle of Man under the Isle of Man Companies Act 2006 with registered number 002845V)

PROPOSED OFFER TO ACQUIRE THE ENTIRE ISSUED SHARE CAPITAL OF APOLLON FORMULARIES LTD NOT ALREADY OWNED

APPROVAL OF WAIVER OF OBLIGATIONS UNDER RULE 9 OF THE CITY CODE ON TAKEOVERS AND MERGERS

CHANGE OF NAME TO APOLLON FORMULARIES PLC

PLACING AND SUBSCRIPTION OF 50,000,000 NEW ORDINARY SHARES AT 5 PENCE PER SHARE

NOTICE OF GENERAL MEETING

AQSE GROWTH MARKET CORPORATE ADVISER AND BROKER

PETERHOUSE CAPITAL LIMITED



The AQSE Growth Market, which is operated by Aquis Exchange PLC, a Recognised Investment Exchange, is a market designed primarily for emerging or smaller companies to which a higher investment risk tends to be attached than to larger or more established companies.

It is not classified as a Regulated Market under EU financial services law and AQSE Growth Market securities are not admitted to the Official List of the Financial Conduct Authority of the United Kingdom ("FCA"). Investment in an unlisted company is speculative and involves a higher degree of risk than an investment in a listed company. The value of investments can go down as well as up and investors may not get back the full amount originally invested. An investment should therefore only be considered by those persons who are prepared to sustain a loss on their investment. A prospective investor should be aware of the risks of investing in AQSE Growth Market securities and should make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser authorised under the FSMA who specialises in advising on the acquisition of shares and other securities.

The Company is required by Aquis Stock Exchange to appoint an AQSE Growth Market Corporate Adviser to apply on its behalf for admission to the AQSE Growth Market and must retain an AQSE Growth Market Corporate Adviser at all times. The requirements for an AQSE Growth Market Corporate Adviser are set out in the Corporate Adviser Handbook and the AQSE Growth Market Corporate Adviser is required to make a declaration to Aquis Stock Exchange in the form prescribed by Appendix B. This Document has not been examined or approved by Aquis Stock Exchange or the Financial Conduct Authority.

Peterhouse Capital Limited (“**Peterhouse**”), which is authorised and regulated by the FCA, is the Company’s AQSE Growth Market Corporate Adviser for the purposes of Admission. Peterhouse has not made its own enquiries except as to matters which have come to its attention and on which it considered it necessary to satisfy itself and accepts no liability whatsoever for the accuracy of any information or opinions contained in this Document, or for the omission of any material information, for which the Existing Directors, Proposed Directors or Concert Parties are solely responsible. Peterhouse is acting for the Company and no one else in relation to the arrangements proposed in this Document and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice to any other person on the content of this Document.

The whole text of this Document should be read. An investment in the Company involves a high degree of risk and, may not be suitable for all recipients of this Document. Prospective investors should consider carefully whether an investment in the Company is suitable for them in the light of their personal circumstances and the financial resources available to them.

OVERSEAS SHAREHOLDERS

This Document does not constitute an offer to sell, or a solicitation to buy Ordinary Shares in any jurisdiction in which such offer or solicitation is unlawful. In particular, this Document is not, subject to certain exceptions, for distribution in or into the United States, Canada, Australia, the Republic of South Africa or Japan. The Ordinary Shares have not been nor will be registered under the United States Securities Act of 1933, as amended, nor under the securities legislation of any state of the United States or any province or territory of Canada, Australia, the Republic of South Africa or Japan or in any country, territory or possession where to do so may contravene local securities laws or regulations. Accordingly, the Ordinary Shares may not, subject to certain exceptions, be offered or sold directly or indirectly in or into the United States, Canada, Australia, the Republic of South Africa or Japan or to any national, citizen or resident of the United States, Canada, Australia, the Republic of South Africa or Japan. The distribution of this Document in certain jurisdictions may be restricted by law. No action has been taken by the Company or Peterhouse that would permit a public offer of Ordinary Shares or possession or distribution of this Document where action for that purpose is required. Persons into whose possession this Document comes should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

Holding Ordinary Shares may have implications for overseas Shareholders under the laws of the relevant overseas jurisdictions. Overseas Shareholders should inform themselves about and observe any applicable legal requirements. It is the responsibility of each overseas Shareholder to satisfy himself as to the full observance of the laws of the relevant jurisdiction in connection therewith, including the obtaining of any governmental, exchange control or other consents which may be required, or the compliance with other necessary formalities which are required to be observed and the payment of any issue, transfer or other taxes due in such jurisdiction.

Copies of this Document will be made available on the website of the Company at <https://www.apollon.org.uk> (please note that information on this website, and information found on other websites linked to this website, does not form part of this Document unless that information is incorporated by reference into this Document).

This document is dated 7 April 2021.

KEY STATISTICS

EXPECTED TIMETABLE OF PRINCIPAL EVENTS

Date of Publication of Supplementary Admission Document	7 April 2021
Latest time and date for receipt of Forms of Proxy for the General Meeting	10 a.m. (London Time) on 8 April 2021
General Meeting	10 a.m. on 12 April 2021
Announcement of the result of the General Meeting	on 12 April 2021
Admission of the Enlarged Share Capital	on 13 April 2021
CREST accounts expected to be credited	on 13 April 2021

PART I
LETTER FROM THE CHAIRMAN OF AFRIAG GLOBAL PLC

Directors:

David Lenigas
Hamish Harris
Donald Strang

Registered Office:

34 North Quay
Douglas, Isle of Man, IM1 4LB

7 April 2021

Dear Shareholder

**PROPOSED OFFER TO ACQUIRE THE ENTIRE ISSUED SHARE CAPITAL OF APOLLON
FORMULARIES LTD**

**APPROVAL OF WAIVER OF OBLIGATIONS UNDER RULE 9 OF THE CITY CODE ON TAKEOVERS
AND MERGERS**

CHANGE OF NAME TO APOLLON FORMULARIES PLC

PLACING AND SUBSCRIPTION OF 50,000,000 NEW ORDINARY SHARES AT 5 PENCE PER SHARE

NOTICE OF GENERAL MEETING

Introduction

Since the posting of the Admission Document dated 17 March 2021, I am writing to bring to your attention an additional risk factors pertaining to the option to acquire Doc's Place International, Inc. and/or CBev Ventures, Inc., with regards to the Proceeds of Crime Act 2002.

Doc's Place International, Inc.

As stated in the Admission Document, Apollon has an option to acquire 90% of the stock of Doc's Place under a **Right to Purchase Understanding ("Doc's Place RPU")**, a company incorporated and existing in the State of Georgia, USA, by 30 June 2021. Such 90% stock interest is owned by Stephen D. Barnhill, M.D., who serves as Doc's Place's sole director and Chief Executive Officer. Stephen D. Barnhill, M.D., is also Chairman and CEO Apollon Formularies, Inc., a U.S. affiliate of AFJ to which he also serves as President and director. Doc's Place has established and operates a Wellness Centre and Resort which is described as being a component of a Global Centre of Excellence for Medical Cannabis Therapy. In addition to such interest and right to purchase, there exists a financing arrangement whereby Apollon has paid and loaned money to Doc's Place for the leasing and development of property and facilities for the establishment of the Wellness Centre. AFJ leases space to and obtains services from Doc's Place in order to be the exclusive medical cannabis retail dispensary and treatment operation located on the premises and to have a destination for patients and their families to have convenient access to accommodations, care and amenities while undergoing treatment in Jamaica. Apollon is also entitled to 95% of the net profits of the business of Doc's Place. Doc's Place, which currently has eight treatment rooms, is approved by the SRC and Ministry of Science, Energy and Technology for the treatment of medical cannabis patients.

CBev Ventures, Inc.

As stated in the Admission Document, Apollon has an exclusive right to purchase the assets and assume certain liabilities and obligations of CBev, a company incorporated and registered in the State of Georgia, USA, as pertain its business under a **Right to Purchase Understanding ("CBev RPU")** by 30 June 2021. CBev is a beverage company that develops, markets and distributes functional and craft beverages in the legal CBD and medical cannabis industries. Stephen D. Barnhill, Jr. is the sole director and Chief Executive Officer of CBev and per the CBev RPU will become a senior vice president of Apollon responsible for leading its worldwide functional beverage division and enter into an employment agreement. Apollon has also provided CBev with £ 64,571 of funding per such arrangement.

Additional Risk Factor pertaining to Doc's Place and/or CBev Ventures, Inc., in the event that either the Doc's Place RPU or CBev RPU is triggered

Further investments by the Company in the medical cannabis and CBD wellness sector and the exercise of its right to purchase in respect of either Doc's Place International Inc. and/or CBev Ventures, Inc. may be precluded by the laws in force from time to time in the United Kingdom

The Directors will take all precautions to ensure that:

- the activities of the Company are in compliance with the laws that are in force in England and Wales, Scotland and Northern Ireland from time to time ("UK Legislation") and the laws, regulations and guidelines of the jurisdictions in which they choose to operate; and
- the Company does not contravene POCA 2002.

The Directors will also ensure that the activities of any companies invested in by the Company in the future are and remain in compliance with the laws, regulations and guidelines of the jurisdictions in which they operate.

However there can be no guarantee that the Company will be able to successfully complete financial, legal, regulatory and technical due diligence in respect of any target company in which it is contemplating an investment **including without limitation the right to purchase which it holds in respect of Doc's Place International Inc. and/or CBev Ventures, Inc.** If the Company fails to obtain:

1. an appropriate and unqualified opinion from suitably experienced and qualified local counsel in the jurisdiction in which any investment targets operate that its activities are in compliance with the local laws, regulations and guidelines; and
2. an appropriate and unqualified opinion from suitably qualified and experienced counsel in England and Wales that the investment targets do not breach UK Legislation, including, without limit, POCA 2002,

then the Company will not be able to complete the investment into such target companies including, without limit, Doc's Place International Inc. and/or CBev Ventures, Inc. This may have material adverse effects on the business, financial condition, results and/or future operations of the Company.

No other significant change

Save as disclosed in this Supplementary Admission Document, there have been no significant changes affecting any matter contained in the Admission Document and no significant new matter has arisen, the inclusion of information in respect of which would have been required to be included in the Admission Document if it had arisen at the time of its preparation.

Recommendation

The Existing Directors, who have been so advised by Peterhouse, consider that the Proposals and Resolutions set out in the notice of General Meeting are fair and reasonable, and in the best interests of the Company and its Shareholders as a whole and accordingly, unanimously recommend Shareholders to vote in favour of the Resolutions to be proposed at the General Meeting. In providing advice to the Directors, Peterhouse has taken into account the Directors' commercial assessments.

Accordingly, the Existing Directors recommend that the Independent Shareholders vote in favour of the Resolutions to be proposed at the General Meeting, as they intend to do in respect of their own holdings of Ordinary Shares which amount, in aggregate, to 2,040,000 Ordinary Shares representing 6.43 per cent. of the Existing Ordinary Shares.

Yours faithfully

David Lenigas

Executive Chairman

DEFINITIONS

The following definitions apply throughout this document, unless the context requires otherwise:

AFJ	Apollon Formularies Jamaica Limited, a private company registered in Jamaica with company number 92237 whose registered office is in Jamaica.
Apollon or AFL	Apollon Formularies Ltd, a private company registered in England and Wales with company number 11489007 and registered address at 7-9 Swallow Street, London, United Kingdom, W1B 4DE.
CBev	CBev Ventures, Inc., a company incorporated and registered in the State of Georgia, USA.
Company	AfriAg Global PLC, a public limited liability company incorporated and registered in the Isle of Man with company number 002845V and registered office address at 34 North Quay, Douglas, Isle of Man, IM1 4LB.
Doc's Place	Doc's Place International, Inc., a company incorporated and registered in the State of Georgia, USA that is a party to a certain RPU with Apollon whereby 90% of its shares can be acquired by Apollon.
Existing Directors	David Lenigas, Hamish Harris and Donald Strang, who are the directors of the Company as at the date of this Document but will be resigning with effect from Admission.
POCA	the Proceeds of Crime Act 2002.
Proposed Directors	together Stephen D. Barnhill, M.D., Nicholas Barnhill, Nicholas Andrew Ingrassia and Kevin Sheil, who will be the directors of the Company with effect from Admission.
RPU	Right to Purchase Understanding.